We are a group of third year neuroscience students. We prepared this seminar presentation about the use of sustained release ocular formulations and their potential to revolutionise the retinal therapeutics market. We chose this topic because it focuses on retinal therapeutics which is a part of our neuroscience studies, but also because some of the members of the group have an interest in business and this tackled the issue of pharmaceutical markets.
You can see/download our presentation here.
Please leave your comments and feedback at the end of this post.
Members of the Team:
Dara Bell. I am a third year neuroscience student from Monaghan. My section involved the current retinal therapeutics market. I chose this because I also have a keen interest in business as well as neuroscience. I was particularly interested in the fact that treatment for Age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) held around 2/3rds of the market yet all the current treatments for both diseases involved intra-vitreal injections.
Lara Gibney. I am also a third year neuroscience student in UCD. My section of the project involves researching the current sustained release drugs on the market available for Age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).
Arron Coleman. I am a third year neuroscience student with a particular interest in cognitive neuroscience. I am passionate about sport, being part of the kitesurfing, wakeboarding and surfing clubs within college. My section of the project involved how the fundamentals of sustained ocular formulations worked and the advantages and disadvantages associated with this form of drug distribution.
Mikey O’Connor. I am a third year neuroscience student from Wexford. I looked at the future possibilities of the sustained release ocular formulations in the retinal therapeutics market. I was particularly interested in the forecasted value of the market as we believed the sustained release ocular formations will revolutionise the market.